Vorolanib

CAS No. 1013920-15-4

Vorolanib( CM082,X-82 )

Catalog No. M21932 CAS No. 1013920-15-4

Vorolanib is an orally active VEGFR/PDGFR dual inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 250 In Stock
2MG 145 In Stock
5MG 227 In Stock
10MG 359 In Stock
25MG 616 In Stock
50MG 870 In Stock
100MG 1181 In Stock
200MG 1572 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Vorolanib
  • Note
    Research use only, not for human use.
  • Brief Description
    Vorolanib is an orally active VEGFR/PDGFR dual inhibitor.
  • Description
    Vorolanib is an orally active VEGFR/PDGFR dual inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CM082,X-82
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR|PDGFR
  • Research Area
    Urinary system/Cancer
  • Indication
    Renal Cell Cancer Metastatic

Chemical Information

  • CAS Number
    1013920-15-4
  • Formula Weight
    439.48
  • Molecular Formula
    C23H26FN5O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:22 mg/ml (50.06 mM; Need ultrasonic)
  • SMILES
    CN(C)C(=O)N1CC[C@@H](C1)NC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bendell JC, et al. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors. Oncologist. 2019 Apr;24(4):455-e121.
molnova catalog
related products
  • SAR131675

    AR131675 is highly selective for VEGFR-3 versus 107 receptors, enzymes, ion channels, and 65 kinases.

  • Ellipticine

    Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action.

  • Pazopanib hydrochlor...

    A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.